Altered motion repulsion in Alzheimer's disease
Yan Li1, Shougang Guo2, Yongxiang Wang2
1Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang City, 471000, China.
Scientific Reports
|January 21, 2017
Summary
Alzheimer's disease (AD) patients show weaker motion repulsion, a visual processing deficit. This finding suggests motion repulsion can be an early biomarker for tracking AD progression.
Area of Science:
- Neuroscience
- Ophthalmology
- Gerontology
Background:
- Perceptual impairments may precede cognitive decline in Alzheimer's disease (AD).
- These early deficits offer potential for noninvasive AD detection and monitoring.
- Visual motion processing is a key area for investigating early AD-related neural changes.
Purpose of the Study:
- To investigate alterations in visual motion processing, specifically direction repulsion, in individuals with Alzheimer's disease (AD).
- To determine if deficits in motion repulsion correlate with the clinical severity of AD.
- To explore motion repulsion as a potential early behavioral biomarker for AD.
Main Methods:
- Utilized random dot kinematograms (RDKs) to present competing visual motion stimuli.
- Measured the magnitude of direction repulsion between two overlapping RDKs moving in different directions.
- Compared motion repulsion in an AD group, an age-matched old control group, and a young control group.
Main Results:
- Motion direction repulsion was significantly weaker in AD patients compared to both young and old healthy controls.
- The magnitude of motion repulsion was found to be predictive of clinical severity assessments in the AD group.
- These findings indicate altered neural functions in visual cortical areas due to AD pathology.
Conclusions:
- A deficit in motion repulsion is a significant indicator of Alzheimer's disease (AD).
- Motion repulsion shows promise as a behavioral biomarker for tracking AD development and severity.
- Altered visual cortical functions are implicated in AD, manifesting as impaired motion perception.
Related Concept Videos
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


